Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Flamen

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Acta Oncologica (Stockholm, Sweden)|July 22, 2022
Circulating DNA in the neoadjuvant setting of early stage colon cancerGiacomo Bregni, Andrea Pretta, Chiara Senti, et al.
NPJ Breast Cancer|January 6, 2024
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 4, 2024
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain TrialGeraldine Gebhart, Marleen Keyaerts, Thomas Guiot, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 12, 2021
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheresHugo Levillain, Oreste Bagni, Christophe M Deroose, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Acta Oncologica (Stockholm, Sweden)|July 22, 2022
Circulating DNA in the neoadjuvant setting of early stage colon cancerGiacomo Bregni, Andrea Pretta, Chiara Senti, et al.
NPJ Breast Cancer|January 6, 2024
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 4, 2024
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain TrialGeraldine Gebhart, Marleen Keyaerts, Thomas Guiot, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 12, 2021
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheresHugo Levillain, Oreste Bagni, Christophe M Deroose, et al.
Pageof 13